FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3025897611> ?p ?o ?g. }

• W3025897611 endingPage "1875" @default.
• W3025897611 startingPage "1869" @default.
• W3025897611 abstract "Abstract Background Pemetrexed and bevacizumab as monotherapies, or in combination, have been approved for maintenance therapy following platinum‐based induction in patients with advanced nonsquamous non‐small cell lung cancer (NSCLC). The differences in the benefits of bevacizumab for treatment during early or late NSCLC have not yet been characterized. Methods We retrospectively analyzed data from 35 patients with advanced naïve NSCLC who had received pemetrexed/platinum with or without bevacizumab followed by maintenance therapy with pemetrexed alone or pemetrexed plus bevacizumab. The data were analyzed using the Kaplan‐Meier method and Cox regression adjusted for risk factors. Patients were grouped according to treatment conditions. Group A received pemetrexed plus platinum followed by pemetrexed alone (Pem‐Pt/Pem). Group B received pemetrexed plus platinum followed by pemetrexed and bevacizumab (Group B; Pem‐Pt/Pem + Bev). Group C received pemetrexed, platinum, and bevacizumab during induction therapy, and pemetrexed as maintenance therapy (Group C; Pem‐Pt + Bev/Pem + Bev). We assessed the significance of introduction of bevacizumab at different stages of treatment. Results A total of 13 (37.1%) patients were included in Group A, nine patients (25.7%) were included in Group B, and 13 patients (37.1%) were included in Group C. Among the 35 patients, 69.2% were male, and the median age was 59 years (range 40–75). The median progression‐free survival (PFS) was 7.7 months (231 days, range 134–410 days) in Group A, 9.3 months (280 days, range 84–565 days) in Group B, and 8.0 months (241 days, range 108–665 days) in Group C. The median PFS was not significantly different among the three groups ( P = 0.233). Similarly, bevacizumab did not significantly affect PFS ( P = 0.630). Conclusions The addition of bevacizumab into induction chemotherapy or maintenance therapy provided limited benefits to PFS in our study, but previous studies suggested that bevacizumab may improve disease control. In that way, we presume that early use of bevacizumab may provide a greater benefit." @default.
• W3025897611 created "2020-05-21" @default.
• W3025897611 creator A5018965590 @default.
• W3025897611 creator A5024068269 @default.
• W3025897611 creator A5043365458 @default.
• W3025897611 creator A5063496433 @default.
• W3025897611 creator A5065380119 @default.
• W3025897611 creator A5079927352 @default.
• W3025897611 creator A5090691776 @default.
• W3025897611 date "2020-05-14" @default.
• W3025897611 modified "2023-10-11" @default.
• W3025897611 title "Treatment with or without bevacizumab as a first‐line and maintenance therapy for advanced non‐squamous non‐small cell lung cancer: A retrospective study" @default.
• W3025897611 cites W1989796113 @default.
• W3025897611 cites W1995975734 @default.
• W3025897611 cites W2005244154 @default.
• W3025897611 cites W2029877928 @default.
• W3025897611 cites W2037139573 @default.
• W3025897611 cites W2060251426 @default.
• W3025897611 cites W2078475819 @default.
• W3025897611 cites W2100785570 @default.
• W3025897611 cites W2112621029 @default.
• W3025897611 cites W2115330744 @default.
• W3025897611 cites W2122145135 @default.
• W3025897611 cites W2122798232 @default.
• W3025897611 cites W2128002599 @default.
• W3025897611 cites W2135140316 @default.
• W3025897611 cites W2144660856 @default.
• W3025897611 cites W2145835533 @default.
• W3025897611 cites W2148367564 @default.
• W3025897611 cites W2151518427 @default.
• W3025897611 cites W2154442955 @default.
• W3025897611 cites W2154581953 @default.
• W3025897611 cites W2239287815 @default.
• W3025897611 cites W2286463708 @default.
• W3025897611 cites W2781525129 @default.
• W3025897611 cites W2805273862 @default.
• W3025897611 cites W2917696006 @default.
• W3025897611 cites W2919530208 @default.
• W3025897611 cites W2937223370 @default.
• W3025897611 cites W2964651105 @default.
• W3025897611 cites W4238604577 @default.
• W3025897611 doi "https://doi.org/10.1111/1759-7714.13469" @default.
• W3025897611 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7327679" @default.
• W3025897611 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32406994" @default.
• W3025897611 hasPublicationYear "2020" @default.
• W3025897611 type Work @default.
• W3025897611 sameAs 3025897611 @default.
• W3025897611 citedByCount "1" @default.
• W3025897611 countsByYear W30258976112021 @default.
• W3025897611 crossrefType "journal-article" @default.
• W3025897611 hasAuthorship W3025897611A5018965590 @default.
• W3025897611 hasAuthorship W3025897611A5024068269 @default.
• W3025897611 hasAuthorship W3025897611A5043365458 @default.
• W3025897611 hasAuthorship W3025897611A5063496433 @default.
• W3025897611 hasAuthorship W3025897611A5065380119 @default.
• W3025897611 hasAuthorship W3025897611A5079927352 @default.
• W3025897611 hasAuthorship W3025897611A5090691776 @default.
• W3025897611 hasBestOaLocation W30258976111 @default.
• W3025897611 hasConcept C126322002 @default.
• W3025897611 hasConcept C141071460 @default.
• W3025897611 hasConcept C143998085 @default.
• W3025897611 hasConcept C167135981 @default.
• W3025897611 hasConcept C2776256026 @default.
• W3025897611 hasConcept C2776694085 @default.
• W3025897611 hasConcept C2777240266 @default.
• W3025897611 hasConcept C2777802072 @default.
• W3025897611 hasConcept C2778239845 @default.
• W3025897611 hasConcept C2778283404 @default.
• W3025897611 hasConcept C71924100 @default.
• W3025897611 hasConceptScore W3025897611C126322002 @default.
• W3025897611 hasConceptScore W3025897611C141071460 @default.
• W3025897611 hasConceptScore W3025897611C143998085 @default.
• W3025897611 hasConceptScore W3025897611C167135981 @default.
• W3025897611 hasConceptScore W3025897611C2776256026 @default.
• W3025897611 hasConceptScore W3025897611C2776694085 @default.
• W3025897611 hasConceptScore W3025897611C2777240266 @default.
• W3025897611 hasConceptScore W3025897611C2777802072 @default.
• W3025897611 hasConceptScore W3025897611C2778239845 @default.
• W3025897611 hasConceptScore W3025897611C2778283404 @default.
• W3025897611 hasConceptScore W3025897611C71924100 @default.
• W3025897611 hasIssue "7" @default.
• W3025897611 hasLocation W30258976111 @default.
• W3025897611 hasLocation W30258976112 @default.
• W3025897611 hasLocation W30258976113 @default.
• W3025897611 hasOpenAccess W3025897611 @default.
• W3025897611 hasPrimaryLocation W30258976111 @default.
• W3025897611 hasRelatedWork W1999852871 @default.
• W3025897611 hasRelatedWork W2003278716 @default.
• W3025897611 hasRelatedWork W2013563962 @default.
• W3025897611 hasRelatedWork W2023460550 @default.
• W3025897611 hasRelatedWork W2774698410 @default.
• W3025897611 hasRelatedWork W2900565625 @default.
• W3025897611 hasRelatedWork W2981092032 @default.
• W3025897611 hasRelatedWork W3029430426 @default.
• W3025897611 hasRelatedWork W3206914879 @default.
• W3025897611 hasRelatedWork W4245028049 @default.
• W3025897611 hasVolume "11" @default.
• W3025897611 isParatext "false" @default.

• next